Rapid Onset Fibrosing Cholestatic Hepatitis C Following Transplant of a Hepatitis C Infected Graft Into a Naïve Recipient

Authors

• Kevin B. Harris, Henry Ford HealthFollow
• Brian K. Theisen, Henry Ford HealthFollow
• Qing Chang, Henry Ford HealthFollow
• Shunji Nagai, Henry Ford HealthFollow
• Syed-Mohammed Jafri, Henry Ford HealthFollow
• Lejla Jakupovic, Henry Ford HealthFollow
• Dilip K. Moonka, Henry Ford HealthFollow

Recommended Citation

Harris KB, Theisen BK, Chang Q, Nagai S, Jafri SR, Jakupovic L, Moonka DK. Rapid Onset Fibrosing Cholestatic Hepatitis C Following Transplant of a Hepatitis C Infected Graft Into a Naïve Recipient. Case Rep Transplant. 2026;2026:9822131.

Document Type

Article

Publication Date

7-6-2026

Publication Title

Case Rep Transplant

Abstract

Fibrosing cholestatic hepatitis (FCH) is a devastating complication that can occur when hepatitis C virus (HCV) recurs following liver transplantation. When it occurs, FCH typically develops between 1 and 6 months following transplant and is associated with markedly elevated HCV levels. With the advent of direct-acting antiviral therapy, FCH C is now a rare occurrence. Here, we describe a rare case of early-onset FCH that occurred when an HCV nucleic acid test (NAT) positive liver graft was transplanted into a hepatitis C naïve recipient. This case highlights the importance of initiation of antiviral therapy as soon as possible following transplantation of an HCV NAT-positive liver graft as recommended by current guidelines.

PubMed ID

42416787

Volume

2026

First Page

9822131

Last Page

9822131